Skip to main content
Top
Published in: Annals of Surgical Oncology 5/2014

01-05-2014 | Erratum

Erratum to: Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival

Authors: J. Bart Rose, MD, MAS, Flavio G. Rocha, MD, Adnan Alseidi, MD, Thomas Biehl, MD, Ravi Moonka, MD, John A. Ryan, MD, Bruce Lin, MD, Vincent Picozzi, MD, Scott Helton, MD

Published in: Annals of Surgical Oncology | Issue 5/2014

Login to get access

Excerpt

An error occurred in the Methods section, which is corrected here. The first sentence in the second paragraph, under the heading “Neoadjuvant Chemotherapy Regimen,” should read:
Eligible patients were started on an eight-cycle course of 1,000 mg/m2 of gemcitabine and 40 mg/m2 of docetaxel given on days 1 and 8, every 21 days, with intermittent restaging by computed tomographic scan and cancer antigen (CA) 19–9 levels.
The sentence as originally published, “Eligible patients were started on an eight-cycle course of 1,000 mg/m2 of gemcitabine and 80 mg/m2 of docetaxel given on days 1 and 8, every 21 days, with intermittent restaging by computed tomographic scan and cancer antigen (CA) 19–9 levels,” is incorrect. …
Metadata
Title
Erratum to: Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival
Authors
J. Bart Rose, MD, MAS
Flavio G. Rocha, MD
Adnan Alseidi, MD
Thomas Biehl, MD
Ravi Moonka, MD
John A. Ryan, MD
Bruce Lin, MD
Vincent Picozzi, MD
Scott Helton, MD
Publication date
01-05-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 5/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-3640-7

Other articles of this Issue 5/2014

Annals of Surgical Oncology 5/2014 Go to the issue